6945.TWO AP Biosciences Inc
- Market cap
- TWD 10.7B
- P/E
- -
- P/B
- 4.77x
- ROE
- -18.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6945.TWO undervalued?
Graham numberThe Graham number of AP Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AP Biosciences Inc fundamental analysis
No fundamental analysis for AP Biosciences Inc yet.
AP Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AP Biosciences Inc
AP Biosciences, Inc. researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in the pre-clinical res…
Full company profileAP Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AP Biosciences Inc annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 138M | 6.99M | 0.00 | 32.3M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 138K | 6.99M | -8.68M | 32.3M | -17.5M | 0.00 | 0.00 |
| Operating Income | 45.0M | -187M | -289M | -347M | -439M | -456M | -519M |
| EBITDA | 52.2K | -178M | -290M | -326M | -404M | -418M | -403M |
| Net Income | 41.7K | -188M | -289M | -339M | -423M | -445M | -435M |
| EPS | 0.00 | -3.89 | -5.48 | -5.24 | -5.61 | -5.20 | -4.46 |
| Balance Sheet | |||||||
| Total Assets | 652K | 579M | 1.10B | 891M | 1.73B | 1.37B | 2.41B |
| Total Liabilities | 9.16K | 21.1M | 4.52M | 107M | 104M | 94.2M | 86.6M |
| Shareholders' Equity | 643K | 558M | 1.10B | 784M | 1.62B | 1.27B | 2.33B |
| Cash & Short-term Investments | 631K | 557M | 1.08B | 740M | 1.54B | 971M | 295M |
| Total Debt | - | - | - | 82.1M | 70.9M | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -17.0K | -169M | -276M | -298M | -358M | -352M | -356M |
| Capital Expenditure | 7.25K | 4.91M | 2.43M | 35.4M | 5.53M | 25.3M | 10.6M |
| Free Cash Flow | -24.3K | -174M | -278M | -333M | -363M | -377M | -367M |
| Ratios | |||||||
| ROE | 6.5% | -33.6% | -26.3% | -43.3% | -26.1% | -35.0% | -18.7% |
| ROA | 6.4% | -32.4% | -26.2% | -38.1% | -24.5% | -32.6% | -18.0% |
| Net Profit Margin | 0.0% | -2,682.8% | - | -1,052.0% | - | - | - |
| Debt to Equity | - | - | - | 0.10x | 0.04x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
AP Biosciences Inc dividends
AP Biosciences Inc has not paid dividends in the last 6 fiscal years.
Who owns AP Biosciences Inc
- Insiders 47.16%
- Institutions 4.00%
- Public & others 48.84%
- Shares outstanding 95.7M
- Free float 54.9M
AP Biosciences Inc company profile
- Company name
- AP Biosciences Inc
- Ticker
- 6945.TWO
- ISIN
- TW0006945009
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No.508, Zhongxiao East Road, Taipei, Taiwan, 115011
- Phone
- 886 2 2653 2886
- Website
- apbioinc.com
About AP Biosciences Inc
AP Biosciences, Inc. researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. It caters to healthcare and biotechnology industries. AP Biosciences, Inc. has strategic collaboration with Delos Capital to discover and develop novel immune-related drug candidates through early clinical proof of concept. The company was founded in 2013 and is based in Taipei, Taiwan.
AP Biosciences Inc management
6- Dr. Jeng-Horng Her Ph.D.Founder, CEO, GM & Director
- Mr. Fucheng HuangDirector of Accounting & Finance and Head of Corporate Governance
- Ms. Tseng WinnieDirector of Administration
- Qiying YangDirector of Legal Department
- Mr. Jhong-Jhe You Ph.D.Vice President of Antibody Discovery
- Mr. Qiqiang TuDirector of Biologics Development